Characterising a human endogenous retrovirus(HERV)-derived tumour-associated antigen: enriched RNA-Seq analysis of HERV-K(HML-2) in mantle cell lymphoma cell lines
dc.contributor.author | Tatkiewicz, W | |
dc.contributor.author | Dickie, J | |
dc.contributor.author | Bedford, F | |
dc.contributor.author | Jones, A | |
dc.contributor.author | Atkin, M | |
dc.contributor.author | Kiernan, M | |
dc.contributor.author | Maze, EA | |
dc.contributor.author | Agit, B | |
dc.contributor.author | Farnham, G | |
dc.contributor.author | Kanapin, A | |
dc.contributor.author | Belshaw, R | |
dc.date.accessioned | 2023-02-20T12:39:26Z | |
dc.date.issued | 2020-12 | |
dc.identifier.issn | 1759-8753 | |
dc.identifier.issn | 1759-8753 | |
dc.identifier.other | 9 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/20463 | |
dc.description.abstract |
Background The cell-surface attachment protein (Env) of the HERV-K(HML-2) lineage of endogenous retroviruses is a potentially attractive tumour-associated antigen for anti-cancer immunotherapy. The human genome contains around 100 integrated copies (called proviruses or loci) of the HERV-K(HML-2) virus and we argue that it is important for therapy development to know which and how many of these contribute to protein expression, and how this varies across tissues. We measured relative provirus expression in HERV-K(HML-2), using enriched RNA-Seq analysis with both short- and long-read sequencing, in three Mantle Cell Lymphoma cell lines (JVM2, Granta519 and REC1). We also confirmed expression of the Env protein in two of our cell lines using Western blotting, and analysed provirus expression data from all other relevant published studies. Results Firstly, in both our and other reanalysed studies, approximately 10% of the transcripts mapping to HERV-K(HML-2) came from Env-encoding proviruses. Secondly, in one cell line the majority of the protein expression appears to come from one provirus (12q14.1). Thirdly, we find a strong tissue-specific pattern of provirus expression. Conclusions A possible dependency of Env expression on a single provirus, combined with the earlier observation that this provirus is not present in all individuals and a general pattern of tissue-specific expression among proviruses, has serious implications for future HERV-K(HML-2)-targeted immunotherapy. Further research into HERV-K(HML-2) as a possible tumour-associated antigen in blood cancers requires a more targeted, proteome-based, screening protocol that will consider these polymorphisms within HERV-K(HML-2). We include a plan (and necessary alignments) for such work. | |
dc.format.extent | 9- | |
dc.format.medium | Electronic-eCollection | |
dc.language | en | |
dc.language.iso | eng | |
dc.publisher | Springer Science and Business Media LLC | |
dc.subject | HERV-K(HML-2) | |
dc.subject | HERV-K | |
dc.subject | Transposable element | |
dc.subject | Cancer immunotherapy | |
dc.subject | Leukemia | |
dc.subject | NGS | |
dc.subject | minION | |
dc.subject | Transcriptomics | |
dc.subject | RNA-Seq | |
dc.title | Characterising a human endogenous retrovirus(HERV)-derived tumour-associated antigen: enriched RNA-Seq analysis of HERV-K(HML-2) in mantle cell lymphoma cell lines | |
dc.type | journal-article | |
dc.type | Article | |
plymouth.author-url | https://www.ncbi.nlm.nih.gov/pubmed/32055257 | |
plymouth.issue | 1 | |
plymouth.volume | 11 | |
plymouth.publisher-url | http://dx.doi.org/10.1186/s13100-020-0204-1 | |
plymouth.publication-status | Published | |
plymouth.journal | Mobile DNA | |
dc.identifier.doi | 10.1186/s13100-020-0204-1 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/School of Biomedical Sciences | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA06 Agriculture, Veterinary and Food Science | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
dc.publisher.place | England | |
dcterms.dateAccepted | 2020-01-14 | |
dc.rights.embargodate | 2023-2-21 | |
dc.identifier.eissn | 1759-8753 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1186/s13100-020-0204-1 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2020 | |
rioxxterms.type | Journal Article/Review |